Core Framework & Diagram How Does Infection Trigger Autoimmunity?
7 月 27, 2026What Is Tumor Microenvironment?
7 月 28, 2026Some infections heal — but the immune system permanently 'mistakes its target' afterward
—— Why a single infection may trigger rheumatoid arthritis, thyroiditis, or even heart disease years later.
I. From infection to autoimmunity: what lies in between?
The key understanding is: infection itself doesn't equal autoimmunity. Infection is a triggering factor, but triggering autoimmunity usually requires three conditions to be simultaneously met: specific genetic susceptibility (certain HLA alleles make specific populations more prone to 'going off course' when responding to specific infections), an infection with particularly strong autoimmune triggering potential, and appropriate timing (when infection occurs affects how the immune system responds). The intersection of all three conditions is the danger zone where autoimmunity occurs.
This also explains why, when the same streptococcal infection occurs, the vast majority of people recover without issue, while only a very small number develop rheumatic heart disease — not because others are 'healthier,' but because of differences in genetic background and timing.
2. Mechanism one: molecular mimicry — the classic case of 'mistaken identity'
In the 1890s, scientists first noticed that strep throat, if treatment is delayed, causes heart valve damage in some patients weeks later (rheumatic heart disease). The answer revealed: Group A Streptococcus's M protein has a highly similar amino acid sequence to part of human cardiac myosin. When the immune system produces antibodies against M protein, these antibodies can simultaneously recognize cardiac myosin — because they 'look so similar.' After the infection subsides and the anti-Streptococcus immune attack stands down, antibodies recognizing cardiac tissue remain, continuously damaging heart valves.
Another classic case: Campylobacter jejuni and Guillain-Barré syndrome (GBS). Campylobacter infection (a common cause of food poisoning) causes approximately one in a thousand infected individuals to develop GBS weeks later — an acute inflammatory demyelinating disease of peripheral nerves that can cause paralysis or even respiratory failure in severe cases. Molecular mimicry mechanism: Campylobacter's lipooligosaccharide structure closely resembles gangliosides in nerve myelin; antibodies targeting the bacteria attack the nerves. GBS treatment, beyond supportive care, uses immunoglobulin infusion or plasma exchange to neutralize these 'misdirected' antibodies.
3. Mechanism two: bystander activation — 'the artillery fire went off course'
Bystander activation's logic differs from molecular mimicry: the immune system didn't misidentify, but surrounding self-tissue was caught in the crossfire during the attack on infection targets. When tissue experiences intense inflammation, large amounts of cytokines (TNF-α, IL-1, IL-6) flood the local environment, activating self-reactive T cells that were originally in a 'dormant' state, allowing them to reactivate.
Viral thyroiditis is a classic example of bystander activation. Certain viruses (coxsackievirus, EBV, COVID-19) directly infect thyroid cells or trigger inflammation around the thyroid. In the local inflammation from the infection, self-reactive T cells against the thyroid are activated and begin attacking thyroid cells. After the infection subsides, some develop Hashimoto's thyroiditis — a potentially lifelong autoimmune state. The 'innocent victim' of bystander activation is often tissue near the infection site, explaining why different viral infections trigger autoimmunity in different locations — depending on where the virus 'chooses' to trigger inflammation.
4. Mechanism three: epitope spreading — the attack keeps widening
Epitope spreading is the mechanism by which autoimmunity 'expands': infection triggers inflammation; inflammation damages some self-tissue; damaged self-cells release protein fragments normally hidden inside cells; dendritic cells present these newly exposed 'self-antigens' to T cells; the immune system identifies these self-proteins as 'new enemies'; more self-tissue is attacked, exposing more 'new antigens,' forming a positive feedback loop.
Systemic lupus erythematosus (SLE) is the most typical disease of epitope spreading — patient self-antibody types tend to increase over the disease course, with the attack range expanding from skin to joints, kidneys, and nervous system. Multiple studies find SLE's initial triggering is highly correlated with EBV infection.
5. COVID-induced autoimmunity — the largest-scale 'natural experiment' of our time
In 2023, a large study covering 1.5 million people published in Nature Medicine found that after COVID infection, the risk of new autoimmune diseases significantly increased — including rheumatoid arthritis (risk increase approximately sixteen percent), inflammatory bowel disease (approximately thirteen percent), systemic lupus erythematosus (approximately twenty-five percent), and antiphospholipid syndrome (approximately fifty-seven percent).
Importantly: this doesn't mean most people infected with COVID will develop autoimmunity — the increase in absolute risk is limited. But for those who already have autoimmune family history or autoimmune tendencies, one infection may be the final triggering factor. This data also reminds us: vaccination not only prevents acute infection but may also reduce post-infection autoimmune risk by reducing infection itself.
6. Genetic susceptibility and personal risk assessment: who needs extra vigilance?
Infection triggering autoimmunity doesn't pose equal risk to everyone. HLA (human leukocyte antigen) genotype is the most important autoimmune genetic risk factor currently known. Certain HLA alleles make carriers more likely to produce 'off-track' immune responses when dealing with specific infections. For example, HLA-DR4 is highly correlated with rheumatoid arthritis risk; HLA-B27 with ankylosing spondylitis; HLA-DQ2/DQ8 with celiac disease. These associations aren't deterministic — most carriers of high-risk HLA genotypes never develop disease — but they're meaningful background risk indicators.
If you have first-degree relatives (parents, siblings) with autoimmune diseases, your genetic susceptibility is higher than the general population. In this context, infection management needs to be more proactive: treat infections promptly and properly (no delays, no stopping medication early); receive all recommended vaccines (especially flu, pneumococcal, shingles); in the weeks after infection, watch closely whether joint pain, rash, increased fatigue, or other new symptoms appear, and proactively inform the doctor of recent infection history.
Another population worth attention: those with 'subclinical autoimmunity' signs — for example, blood tests finding antinuclear antibody (ANA) positive, but no confirmed autoimmune disease diagnosis yet. These people are in autoimmunity's 'gray zone': the immune system has started producing self-antibodies, but damage is insufficient to trigger clinical symptoms. For this group, one serious infection may be the triggering factor pushing subclinical status to clinical diagnosis. If you know you have positive self-antibodies, take infection prevention and timely treatment more seriously, and maintain regular follow-up with rheumatology/immunology to monitor changes in autoimmune indicators.
For those already diagnosed with autoimmune diseases, understanding infection triggering mechanisms has another layer of practical value: it suggests that during and after every infection, autoimmune disease activity status needs more careful monitoring. Many autoimmune disease acute flares happen weeks after infection — this isn't coincidental, but infection reactivating autoimmune processes that were previously suppressed. If you have rheumatoid arthritis, lupus, multiple sclerosis, or inflammatory bowel disease and experience symptom worsening after an infection (including ordinary colds), tell your specialist promptly rather than waiting for it to 'pass on its own.'
Frequently Asked Questions